Bolden Therapeutics

Bolden Therapeutics is a preclinical-stage biotechnology company developing first-in-class therapeutics to treat central nervous system diseases by stimulating the endogenous formation of new brain cells. Bolden’s research has demonstrated enhanced neurogenesis in mice via targeting a novel signaling pathway, and the company has multiple antisense oligonucleotide candidates in preclinical study. Our target clinical indications include neurodegenerative conditions (e.g., Alzheimer’s disease), mood disorders (e.g., treatment resistant depression) and brain injury (including recovery from stroke). Bolden’s scientific underpinnings come from the laboratories of Drs Justin Fallon and Ashley Webb, both professors of Neuroscience and Molecular Biology respectively at Brown University.